PhaseV is organizing the RISW 2026 session on agentic AI in regulatory science featuring three leaders from JHU, FDA, and Takeda.

PhaseV is a Boston-based technology company transforming clinical development with an enterprise-ready AI/ML platform that accelerates decisions, de-risks trials, and drives portfolio efficiency. Its Trial Optimizer designs smarter studies, reducing costs by up to 50%, lowering enrollment needs by 40%, shortening timelines by 40%, and boosting probability of success by 30%+. The ClinOps Optimizer enhances site selection by integrating patient-level insights with real-time dashboards to track performance. The Lifecycle Management module combines causal evidence, development complexity, and market value to inform portfolio decisions. Together, these solutions enable sponsors and CROs to optimize every stage of development.